These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 22761464)

  • 1. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
    Watanabe T; Tobinai K; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Kashihara T; Iida S
    Br J Haematol; 2016 Mar; 172(5):745-56. PubMed ID: 26732066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
    Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
    Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
    Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
    Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
    Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
    Pautasso C; Bringhen S; Cerrato C; Magarotto V; Palumbo A
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1371-9. PubMed ID: 23834482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
    Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
    Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.